Abstract
Pathological cardiac stimulation by angiotensinII (AngII) can cause left ventricular hypertrophy, a major independent risk factor for heart attack and death. We have previously reported that AngII exerts its hypertrophic effects by usurping the epidermal growth factor (EGF) signalling pathway via metalloprotease-dependent transactivation. However, the EGF-like ligand responsible for AngII-mediated transactivation and cardiac hypertrophy remains to be identified. Using phosphorylated ERK1/2 as a read-out of growth pathway activation and an alkaline phosphatase-tagged Heparin-Binding EGF-like Growth Factor (HB-EGF) reporter construct to examine AngII-mediated liberation, we provide evidence that HB-EGF is the soluble growth factor involved in AngII-induced left ventricular hypertrophy.
Similar content being viewed by others
References
de Gasparo, M., et al., Pharmacol. Rev., 52(3) (2000) 415–472.
Olson, E.N. and Srivastava, D., Science, 272(5262) (1996) 671–676.
Bokemeyer, D., Schmitz, U. and Kramer, H.J., Kidney Int., 58 (2) (2000) 549–558.
Zwick, E., et al., J. Biol. Chem., 272(40) (1997) 24767–24770.
Thomas, W.G., et al., Circ. Res., 90(2) (2002) 135–142.
Daub, H., et al., Nature, 379(6565) (1996) 557–560.
Prenzel, N., et al., Endocr. Relat. Cancer, 8(1) (2001) 11–31.
Prenzel, N., et al., Nature, 402(dy6764) (1999) 884–888.
Hannan, R.D., et al., Proc. Natl. Acad. Sci. USA, 93(16) (1996) 8750–8755.
Hannan, R.D., et al., Physiol, 30(8) (2003) 517–527.
Levitzki, A. and Gazit, A., Science, 267(5205) (1995) 1782–1788.
Suzuki, M., et al., J. Biol. Chem., 272(50) (1997) 31730–31737.
Yu, W.H., et al., Genes. Dev., 16(3) (2002) 307–323.
Izumi, Y., et al., Embo. J., 17(24) (1998) 7260–7272.
Yan, Y., Shirakabe, K. and Werb, Z., J. Cell. Biol., 158(2) (2002) 221–226.
Asakura, M., et al., Nat. Med., 8(1) (2001) 35–40.
Sunnarborg, S.W., et al., J. Biol. Chem., 277(15) (2002) 12838–12845.
Chen, B., et al., Nat. Genet., 24(3) (2000) 296–299.
Crone, S.A., et al., Nat. Med., 8(5) (2002) 459–465.
Iwamoto, R., et al., Proc. Natl. Acad. Sci. USA, 100(6) (2003) 3221–3226.
Baselga, J., Semin. Oncol., 27(5 Suppl 9) (2000) 27–32.
Visse, R. and Nagase, H., Circ. Res., 92(8) (2003) 827–839.
Suzuki, J., et al., Circ. Res., 73(3) (1993) 439–447.
Nio, Y., et al., J. Clin. Invest., 95(1) (1995) 46–54.
Fujii, N., et al., Biochem. Biophys. Res. Commun., 212(2) (1995) 326–333.
Hoffmann, S., et al., J. Mol. Med., 79(10) (2001) 601–608.
Paradis, P., et al., Proc. Natl. Acad. Sci. USA, 97(2) (2000) 931–936.
Pfeffer, J.M., et al., Proc. Natl. Acad. Sci. USA, 79(10) (1982) 3310–3314.
Dahlof, B., Am. J. Hypertens., 14(2) (2001) 174–182.
Davis-Fleischer, K.M. and Besner, G.E.,Front. Biosci., 3 (1998) d288–d299.
Mende, U., et al., Proc. Natl. Acad. Sci. USA, 95(23) (1998) 13893–13898.
Adams, J.W., et al., Proc. Natl. Acad. Sci. USA, 95(17) (1998) 10140–10145.
Seta, K., et al., J. Biol. Chem., 277(11) (2002) 9268–9277.
Doan, T.N., Ali, M.S. and Bernstein, K.E., J. Biol. Chem., 276(24) (2001) 20954–20958.
Seta, K. and Sadoshima, J., J. Biol. Chem., 278(11) (2003) 9019–9026.
Zhao, Y.Y., et al., J. Biol. Chem., 273(17) (1998) 10261–10269.
Baliga, R.R., et al., Am. J. Physiol., 277(5 Pt 2) (1999) H2026–H2037.
Riese, D.J, 2nd and Stern, D.F., Bioessays, 20(1) (1998) 41–48.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, N.J., Hannan, R.D., Thomas, W.G. et al. AngiotensinII mediates cardiomyocyte hypertrophic growth pathways via MMP-dependent HB-EGF liberation. Int J Pept Res Ther 10, 431–435 (2003). https://doi.org/10.1007/s10989-004-2398-3
Issue Date:
DOI: https://doi.org/10.1007/s10989-004-2398-3